Clearing the debris in Germany

As the shakeout in the German biotech industry speeds up, BioAgency AG, a Hamburg venture capital and consulting company, is changing its focus to concentrate on finding the nuggets among the assets of failed biotech companies.

"We started with a focus on seed and early stage phases," said Björn Lindemann, BioAgency's managing director who is responsible for scientific and technical evaluation and support. "We were offering venture capital, consulting, support, a contact network and other services for young life sciences companies, and had a regional focus on Hamburg."...